307 related articles for article (PubMed ID: 27655700)
1. Shikonin potentiates the effect of arsenic trioxide against human hepatocellular carcinoma in vitro and in vivo.
Song J; Zhao Z; Fan X; Chen M; Cheng X; Zhang D; Wu F; Ying X; Ji J
Oncotarget; 2016 Oct; 7(43):70504-70515. PubMed ID: 27655700
[TBL] [Abstract][Full Text] [Related]
2. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB.
Ma Y; Wang J; Liu L; Zhu H; Chen X; Pan S; Sun X; Jiang H
Cancer Lett; 2011 Feb; 301(1):75-84. PubMed ID: 21078540
[TBL] [Abstract][Full Text] [Related]
3. Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
Li W; Wang M; Wang L; Ji S; Zhang J; Zhang C
Cell Biochem Biophys; 2014 Mar; 68(2):427-36. PubMed ID: 23975599
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
Zhai B; Jiang X; He C; Zhao D; Ma L; Xu L; Jiang H; Sun X
Tumour Biol; 2015 Apr; 36(4):2323-34. PubMed ID: 25416439
[TBL] [Abstract][Full Text] [Related]
5. Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression.
Yang X; Sun D; Tian Y; Ling S; Wang L
Tumour Biol; 2015 Apr; 36(4):2957-64. PubMed ID: 25492486
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of cisplatin-induced colon cancer cells apoptosis by shikonin, a natural inducer of ROS in vitro and in vivo.
He G; He G; Zhou R; Pi Z; Zhu T; Jiang L; Xie Y
Biochem Biophys Res Commun; 2016 Jan; 469(4):1075-82. PubMed ID: 26740178
[TBL] [Abstract][Full Text] [Related]
7. Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
Jiang H; Ma Y; Chen X; Pan S; Sun B; Krissansen GW; Sun X
Cancer Sci; 2010 Apr; 101(4):975-83. PubMed ID: 20219070
[TBL] [Abstract][Full Text] [Related]
8. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
Liu ZM; Tseng JT; Hong DY; Huang HS
Biochem J; 2011 Sep; 438(2):349-58. PubMed ID: 21649584
[TBL] [Abstract][Full Text] [Related]
9. PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair.
Luo Q; Li Y; Deng J; Zhang Z
Chem Biol Interact; 2015 Jan; 226():12-22. PubMed ID: 25499136
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells.
Chen G; Wang K; Yang BY; Tang B; Chen JX; Hua ZC
Int J Oncol; 2012 Jan; 40(1):139-47. PubMed ID: 21947421
[TBL] [Abstract][Full Text] [Related]
11. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
[TBL] [Abstract][Full Text] [Related]
12. microRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma.
Zhu C; Zhou R; Zhou Q; Chang Y; Jiang M
Life Sci; 2016 Dec; 166():34-40. PubMed ID: 27717846
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells.
Chiu HW; Tseng YC; Hsu YH; Lin YF; Foo NP; Guo HR; Wang YJ
Cancer Lett; 2015 Jan; 356(2 Pt B):762-72. PubMed ID: 25449439
[TBL] [Abstract][Full Text] [Related]
14. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Wang W; Adachi M; Zhang R; Zhou J; Zhu D
Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
[TBL] [Abstract][Full Text] [Related]
15. The role of NF-κB in PARP-inhibitor-mediated sensitization and detoxification of arsenic trioxide in hepatocellular carcinoma cells.
Luo Q; Li Y; Lai Y; Zhang Z
J Toxicol Sci; 2015 Jun; 40(3):349-63. PubMed ID: 25972196
[TBL] [Abstract][Full Text] [Related]
16. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.
Zheng T; Yin D; Lu Z; Wang J; Li Y; Chen X; Liang Y; Song X; Qi S; Sun B; Xie C; Meng X; Pan S; Liu J; Jiang H; Liu L
Mol Cancer; 2014 May; 13():133. PubMed ID: 24884809
[TBL] [Abstract][Full Text] [Related]
17. Combination of Poly I:C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells.
Shen P; Jiang T; Lu H; Han H; Luo R
Cell Biol Int; 2011 Aug; 35(8):803-10. PubMed ID: 21418039
[TBL] [Abstract][Full Text] [Related]
18. SurvivinT34A increases the therapeutic efficacy of arsenic trioxide in mouse hepatocellular carcinoma models.
Huang A; Yue D; Liao D; Cheng L; Ma J; Wei Y; Tong A; Cheng P
Oncol Rep; 2016 Dec; 36(6):3283-3290. PubMed ID: 27748945
[TBL] [Abstract][Full Text] [Related]
19. Synergic effect of 3'-azido-3'-deoxythymidine and arsenic trioxide in suppressing hepatoma cells.
Chen C; Zhang Y; Wang Y; Huang D; Xi Y; Qi Y
Anticancer Drugs; 2011 Jun; 22(5):435-43. PubMed ID: 21502917
[TBL] [Abstract][Full Text] [Related]
20. Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells.
Lee PC; Kakadiya R; Su TL; Lee TC
Neoplasia; 2010 May; 12(5):376-87. PubMed ID: 20454509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
